What Can a Dialysis Patient Take for Constipation?

Dialysis patients have several safe options for constipation, but the choices are narrower than for the general population because some widely available over-the-counter products can cause life-threatening electrolyte problems when kidney function is gone. Osmotic laxatives like polyethylene glycol (MiraLAX), stimulant laxatives like senna, and lactulose are among the options most commonly used, while magnesium-containing products and sodium phosphate enemas sit firmly on the “do not use” list. The details matter, though, because constipation in dialysis patients is not just uncomfortable; it’s remarkably common and tied to complications that go well beyond the gut.

Why Constipation Hits Dialysis Patients So Hard

Constipation affects dialysis patients at rates far higher than the general population. A recent systematic review pooling data from over 4,900 hemodialysis patients across 22 studies found a prevalence of about 42%.¹ Individual studies have reported rates as high as 63% in hemodialysis and 29% in peritoneal dialysis patients, with hemodialysis patients facing roughly three times the risk compared to those on peritoneal dialysis.² Other surveys have reported even higher numbers in certain populations.³

The reasons stack up. Dialysis patients deal with fluid restrictions that keep stool hard, dietary limits on fruits and vegetables (to control potassium and phosphorus) that slash fiber intake, reduced physical activity, and medications that slow the gut. Altered gut bacteria and reduced gastrointestinal motility, both consequences of kidney disease itself, add to the problem.⁴ Among medications, phosphate binders deserve special mention. These drugs are prescribed to nearly every dialysis patient to keep phosphorus levels in check, but they are notorious for causing gastrointestinal distress.⁵ Sevelamer, one of the most widely prescribed phosphate binders, carries the highest constipation risk of any drug in its class.⁶

Laxatives That Are Dangerous on Dialysis

Before getting to what’s safe, it helps to know what’s genuinely dangerous, because a couple of these products are sitting in nearly every medicine cabinet.

Magnesium-based laxatives (Milk of Magnesia, magnesium citrate) are the biggest concern. Healthy kidneys clear excess magnesium efficiently, so these products are harmless for most people. When kidneys can’t do the job, magnesium accumulates rapidly. A case report documented a dialysis patient who took Milk of Magnesia and developed magnesium levels above 10 mg/dL, more than four times the upper limit of normal. He went into cardiac arrest, required resuscitation, and needed emergency hemodialysis to bring levels down.⁷ Severe hypermagnesemia can mimic a heart attack, cause dangerously low blood pressure, stop breathing, and drop body temperature. The message is simple: dialysis patients should not take any laxative or antacid containing magnesium.

Sodium phosphate enemas (Fleet enemas) are the other major hazard. In patients with impaired kidneys, the phosphate load from even a single standard-dose enema can push blood phosphorus to extreme levels while crashing calcium. A review from a single medical center found that nearly half of patients who developed severe metabolic problems from sodium phosphate enemas died.⁸ Patients with kidney disease, older age, and poor gut motility are at the highest risk, and alternative preparations like plain saline enemas are recommended instead.⁹

Osmotic Laxatives That Are Generally Safe

Polyethylene glycol 3350, sold as MiraLAX and various store brands, is one of the most commonly recommended first-line options for dialysis patients. It works by holding water in the stool without being absorbed into the bloodstream, which means it doesn’t introduce problematic electrolytes. Multiple clinical trials have confirmed its safety and effectiveness for chronic constipation across a wide age range, and the American College of Gastroenterology has given it a top-tier recommendation for improving stool frequency and consistency.¹⁰ Because it does not rely on kidney clearance and doesn’t add sodium, magnesium, or phosphate to the body, polyethylene glycol is widely considered safe in dialysis patients. Typical use involves dissolving a capful in water and drinking it daily, adjusting the dose based on results.

Lactulose is another osmotic laxative that performs well in this population. It’s a synthetic sugar that passes undigested to the colon, where gut bacteria ferment it, drawing water into the stool and softening it. Research has actually pointed to lactulose as having potential kidney-protective properties beyond its laxative effect.⁴ Lactulose is available by prescription in many countries and over the counter in others. The main downsides are bloating and gas, which often improve as the body adjusts.

Stimulant Laxatives

Senna (Senokot) and bisacodyl (Dulcolax) are stimulant laxatives that work by triggering contractions in the intestinal wall and drawing fluid into the bowel. For years, there was concern that long-term use of stimulant laxatives could damage the nerve cells of the colon, but that fear has been largely set aside by more recent evidence. In dialysis patients specifically, senna has an interesting track record. A randomized controlled trial in hemodialysis patients found that senna glycoside not only relieved constipation but actually lowered serum potassium levels, with no serious adverse events reported during the study period.¹¹ That potassium-lowering effect is a meaningful secondary benefit in a population that routinely struggles with high potassium.

Bisacodyl is also used, though it has less dialysis-specific research behind it. Both senna and bisacodyl are available over the counter and are commonly taken at bedtime for a morning bowel movement. They’re not typically recommended as daily long-term therapy for general constipation, but in dialysis patients whose constipation is chronic and unremitting, regular use under medical guidance is common.

Prescription Medications for Stubborn Constipation

When over-the-counter options aren’t enough, several prescription drugs offer additional relief. These are worth knowing about because dialysis patients often exhaust first-line treatments and assume nothing else exists.

• Lubiprostone (Amitiza): This drug increases fluid secretion in the intestine. Like lactulose, it has shown potential protective effects on kidney function in addition to relieving constipation.
• Linaclotide (Linzess) and plecanatide (Trulance): Both of these work locally in the gut with very limited absorption into the bloodstream, which makes them appear safe in patients with kidney disease.
• Tenapanor (Ibsrela): Originally developed for irritable bowel syndrome with constipation, tenapanor blocks sodium uptake in the intestine and also reduces phosphate absorption. That dual action is particularly useful for dialysis patients dealing with both constipation and high phosphorus.
• Prucalopride (Motegrity): This drug stimulates the gut’s motility directly, helping move contents along. It’s used when conventional laxatives have failed. In patients with kidney disease, the dose should be reduced to 1 mg once daily rather than the standard 2 mg.

All of these options have been reviewed in the context of chronic kidney disease, and researchers have highlighted their potential advantages over traditional bulking and osmotic agents, which can sometimes have limited effectiveness in this population.⁴ Elobixibat, a bile acid transporter inhibitor available in Japan, has also been studied specifically in hemodialysis patients, with long-term treatment significantly increasing bowel movement frequency and improving stool consistency over observation periods lasting up to several years.¹²

The Fiber Question

Fiber is the standard first recommendation for constipation in healthy adults, but it sits in an awkward space for dialysis patients. On one hand, low fiber intake is recognized as a major contributor to constipation in this group.⁴ On the other, many high-fiber foods are also high in potassium or phosphorus, making them restricted on typical dialysis diets. And bulking agents like psyllium need adequate fluid intake to work properly; without enough water, they can actually make things worse by creating a dry, bulky mass in the colon.

Researchers have started investigating whether psyllium husk supplementation can be used safely in dialysis patients. A pilot randomized controlled trial evaluated the feasibility and safety of psyllium in peritoneal dialysis patients, and while the results are early-stage, the fact that such trials are being conducted reflects growing interest in finding fiber-based solutions that fit within the constraints of a dialysis diet.¹³ In the meantime, your renal dietitian can help identify lower-potassium sources of fiber, like white bread made with added fiber, certain cooked vegetables, and small portions of berries, that can modestly increase intake without blowing past electrolyte limits.

How Laxatives Affect Potassium

One of the more interesting developments in this field is the recognition that laxatives may actually help control potassium in dialysis patients, not just relieve constipation. The colon becomes a more important route for potassium excretion as kidney function declines, and stimulating colonic motility with laxatives appears to enhance that process.¹⁴

A large cohort study of more than 36,000 veterans transitioning to end-stage kidney disease found that laxative use was associated with a significantly lower risk of hyperkalemia (potassium above 5.5 mEq/L) without increasing the risk of low potassium.¹⁵ The senna trial mentioned earlier confirmed this in a controlled setting, with patients taking senna seeing measurable drops in serum potassium compared to controls.¹¹ This dual benefit is worth discussing with your nephrologist, especially if hyperkalemia is an ongoing battle alongside constipation.

Tracking What’s Working

Because constipation in dialysis is chronic and multifactorial, finding the right regimen often involves trial and adjustment. Keeping track of bowel movement frequency and stool consistency can help you and your care team figure out whether a treatment is actually working or just creating side effects. Research on hemodialysis patients has shown that quality of life around constipation improves in parallel with stool consistency scores and bowel movement frequency, and that patients who track these measures using simple tools like the Bristol Stool Scale can better communicate their symptoms to providers.¹⁶ This is not high-tech self-monitoring; it’s jotting down how often you go and whether the stool was hard, soft, or watery. That information makes dialysis visits more productive when constipation comes up.

Constipation, Gut Bacteria, and Uremic Toxins

There is a less obvious reason to take constipation seriously on dialysis, one that goes beyond comfort. When stool sits in the colon for an extended time, gut bacteria have more opportunity to ferment protein into compounds called uremic toxins. These are substances that healthy kidneys would normally filter out but that accumulate in kidney disease. A prolonged colonic transit time, along with a diet that’s relatively high in protein compared to fiber, promotes the generation and absorption of these bacterial toxins.¹⁷

The practical implication is that treating constipation in dialysis patients may not just improve quality of life and help control potassium. It could, at least in theory, reduce the overall burden of uremic toxins between dialysis sessions. Researchers have described this as part of a broader picture in which gut health and kidney health are more intertwined than previously appreciated. Phosphate binders, which are necessary for controlling phosphorus, may themselves alter the gut microbiome in ways that worsen this cycle.⁵ The result is something of a catch-22: medications that dialysis patients need for survival contribute to constipation, and constipation itself may make the metabolic consequences of kidney failure worse.

Herbal Supplements and What to Watch For

Herbal laxatives are common in the general population, and dialysis patients are not immune to their appeal. Surveys have found that roughly one in five dialysis patients uses herbal products, with a majority open to trying them.¹⁸ The problem is that many herbal laxatives contain undisclosed amounts of minerals, electrolytes, or active compounds that could interact unpredictably with kidney failure. Some contain oxalates, some contain potassium, and many have not been tested for safety in people with no kidney function at all.

Senna, although plant-derived, has crossed the line into well-studied pharmaceutical territory and is distinct from most herbal products in that its active ingredient is standardized and researched. Aloe vera juice, cascara sagrada, and various traditional teas are not in the same category. If you’re considering any herbal product for constipation, the safest move is to bring the label to your nephrologist or renal dietitian before using it. The risk isn’t just that these products might not work; it’s that their mineral content could create the same kind of electrolyte emergencies as magnesium or phosphate-based laxatives.

Differences Between Hemodialysis and Peritoneal Dialysis

Constipation rates differ between hemodialysis and peritoneal dialysis patients, with hemodialysis patients consistently reporting higher rates. One reason is that hemodialysis patients tend to have stricter fluid restrictions, since they produce less urine and fluid accumulates between treatments. Peritoneal dialysis patients often have somewhat more liberal fluid allowances because the dialysis solution continuously removes fluid through the peritoneal membrane. Still, constipation rates among peritoneal dialysis patients are not trivial; studies have placed them anywhere from about 29% to over 70% depending on how constipation is defined and who is being surveyed.^{2 3}

For peritoneal dialysis patients specifically, constipation carries an additional mechanical risk. A colon distended with stool can press against the peritoneal catheter or interfere with dialysis fluid drainage, leading to poor dialysis efficiency or catheter malfunction. That makes proactive constipation management even more important in this group. The treatment options themselves are largely the same as for hemodialysis patients: polyethylene glycol, lactulose, and senna are all used, with the same cautions about magnesium and phosphate products. The main difference is practical rather than pharmacological. Because peritoneal dialysis is done at home, patients often need clearer self-management guidance about when to escalate treatment on their own versus calling their clinic.

Despite the high prevalence and genuine clinical consequences of constipation in dialysis, published data on the safety and effectiveness of specific treatments in this population remain surprisingly thin.¹⁹ Most of the recommendations used in practice are extrapolated from general-population studies or based on clinical experience rather than large trials conducted specifically in dialysis patients. That gap is starting to close, but it means working closely with your kidney care team to find the right combination is still more art than algorithm.